Effects of transplanted pituitary tumors on host pituitary prolactin secretion

Effects of dopamine d2 receptor agonists in a pituitary transplantation-induced hyperprolactinaemia/anovulation model in rats

1. In the present study, we investigated the effects of hyperprolactinaemia, induced by transplantation of anterior pituitary glands under the kidney capsule in female rats, on the relationship between serum and pituitary concentrations of the gonadotropins and on the oestrous cycle. 2. Rats with pituitary transplants showed increased serum prolactin concentrations and decreased serum concentrations of gonadotropins and increased pituitary concentrations of gonadotropins. Moreover, these rats showed persistent dioestrous and anovulation from 3 to 6 days after transplantation. 3. A single oral administration of cabergoline (at doses between 0.001 and 0.1 mg/kg) dose-dependently inhibited the elevated serum prolactin concentrations in hyperprolactinaemic rats. At 0.1 mg/kg, cabergoline induced a continuous reduction in serum prolactin concentrations for 5 days after administration. Terguride (0.1 mg/kg) and bromocriptine (10 mg/kg) also reduced serum prolactin concentrations at 1 and 3 days after administration. All three dopamine D2 receptor agonists increased serum gonadotropin concentrations and ovarian weight at 3 days after administration. 4. In rats exhibiting anovulation, a single oral administration of any one of the three dopamine D2 receptor agonists dose-dependently restored ovulation and a normal oestrous cycle appeared. Oral administration of cabergoline (0.03 mg/kg) or terguride (0.1 mg/kg) restored ovarian function and abolished the anovulation following a reduction in serum prolactin concentrations. However, bromocriptine (10 mg/kg) did not completely abolish anovulation. Following administration of terguride (0.3 mg/kg) or bromocriptine (30 mg/kg), only one normal oestrous cycle appeared; however, following cabergoline (0.1 mg/kg), two normal oestrous cycles appeared. 5. These results suggest that cabergoline has a potent and long-lasting action as a dopamine D2 receptor agonist and, thus, should be a useful drug for the treatment of galactorrhoea and hyperprolactinaemic amenorrhoea and/or anovulation in humans.

Effect of human prolactin administration on gonadotropin and thyrotropin secretion in normal men

To test the hypothesis that PRL is able to feedback negatively on its own secretion (short-loop feedback) in humans via augmentation of the turnover of tuberoinfundibular dopamine (TIDA), the effects of the administration of purified hPRL on endogenous LH, FSH and TSH were assessed. Purified hPRL, given in an i.v. loading dose of 90 micrograms followed by a continuous infusion of 1.39 micrograms/min to 4 normal male volunteers resulted in a tripling of PRL levels (10.5 +/- 1.9 micrograms/L increasing to 30.9 +/- 3.6 micrograms/L) at the end of 90 min. There were no changes in LH, FSH or TSH levels, however, during or following the infusion. Purified hPRL was also given in 1 and 8 micrograms/kg doses IM to 5 normal male volunteers. Although PRL levels did not rise significantly with the 1 microgram/kg dose, levels almost doubled with the 8 micrograms/kg dose (9.5 +/- 2.2 micrograms/L increasing to 17.4 +/- 1.5 micrograms/L). Again, LH, FSH and TSH levels did not change significantly over the three hour period of sampling with either dose. In conclusion, in this study we found that a 2-3 fold increase of circulating PRL levels maintained for 1.5-3 h exerted no apparent effects on the secretion of endogenous LH, FSH and TSH. This study provides direct evidence against the existence of a short-loop feedback occurring via TIDA activation in humans over this time interval but does not rule out the possibility that such feedback may occur with more prolonged states of hyperprolactinemia or via other mechanisms or the possibility of an effect on the hypothalamic pulse generator.

Acute inhibition of PRL and TSH secretion after intraventricular injection of PRL in ovariectomized rats

Prolactin (PRL) is under short-loop inhibitory control via the hypothalamus. However, earlier studies evaluated the effects on PRL secretion of PRL levels elevated for periods of days. In this study we evaluated the acute effects of intraventricular and systemic injection of PRL on the release of a variety of pituitary hormones. Ovariectomized (OVX) rats, bearing implanted third ventricular and jugular cannulas were used. Blood was withdrawn in unanesthetized, freely moving animals before and after intraventricular injection of 0.9% NaCl or 1 or 3 micrograms of bovine (b) or ovine (o) PRL. Prolactin was also administered intravenously in doses of 3 or 6 micrograms. No effect on plasma levels of any of the pituitary hormones occurred after intraventricular or systemic injection of saline. Intraventricular injection of both doses of bPRL or oPRL significantly lowered plasma PRL within 15-30 min. In animals with elevated initial PRL values because of stress or estradiol (E) priming, greater lowering of PRL occurred. Inconsistent reductions in plasma PRL occurred after intravenous injection of oPRL but not bPRL, which elevated PRL values via cross-reaction in the immunoassay. In contrast, only small and inconsistent declines in luteinizing hormone (LH) were seen after intraventricular injection of PRL in either OVX or OVX E-primed rats. Plasma follicle-stimulating hormone (FSH) and growth hormone (GH) were not affected by PRL in any of the experiments; however, a significant lowering of thyrotropin (TSH) occurred in OVX or OVX E-primed rats within 30 min after intravenous injection of 3 micrograms of oPRL, but no change occurred after intravenous PRL. The data indicate that PRL can acutely inhibit PRL and TSH release via a hypothalamic action, whereas release of LH is only slightly inhibited and that of FSH and GH is unaltered.

The influence of long term estrogen treatment on plasma prolactin levels induced by ether anesthesia in ovariectomized rats

2 methods of continuous estrogen delivery, polyestradiol phosphate injection and implantation of Silastic capsules of estradiol-17 beta, in ovariectomized rats induced increases in plasma prolactin in the afternoon (15.00-17.00) beginning at 1 week and continuing for 4-8 weeks. In addition these methods of estrogen treatment potentiated the ether-induced increase in plasma prolactin in the morning (9.00-11.00) beginning on week 2 and continuing for 3-8 weeks. These results indicate that estrogen activates the mechanisms that cause an afternoon surge in prolactin before potentiating a morning elevation induced by ether anesthesia.

Prolactin

Prolactin exists in man as a distinct and separate anterior pituitary hormone from growth hormone. It is important in lactation and the control of gonadal function, although it may have a much wider and basic metabolic role, similar to its role in lower forms. In clinical endocrinology it is important as an index of pituitary and hypothalamic diseases; thus prolactin levels are elevated in association with these conditions and this reflects the normal tonic inhibitory hypothalamic control of prolactin by PIF; DA is the most important PIF. Hyperprolactinaemia causes hypogonadism in both men and women; it may present in women with amenorrhoea, oligomenorrhoea, polymenorrhoea, regular cycles with anovulation or a defective luteal phase, and impotence in men. In either sex galactorrhoea is reported to occur in only 30 per cent of patients. Neurotransmitter therapy, with dopamine agonists which act as functional analogues of PIF, restores prolactin levels to normal and leads to a return of normal gonadal function. The mechanism of the hypogonadism is not clear and is discussed together with the problems associated with inducing pregnancy in these patients, who may harbour microadenomata of the pituitary.